{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:10:14Z","timestamp":1762762214286,"version":"3.40.5"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejim.2024.06.012","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T15:46:18Z","timestamp":1718466378000},"page":"140-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Pioneering the future: CRISPR-Cas9 gene therapy for hereditary hemorrhagic telangiectasia"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1837-2459","authenticated-orcid":false,"given":"Michael","family":"James","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6084-9792","authenticated-orcid":false,"given":"Viren S.","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2024.06.012_bib0001","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejim.2023.08.024","article-title":"New genetic drivers in hemorrhagic hereditary telangiectasia","volume":"119","author":"Cerd\u00e0","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"7","key":"10.1016\/j.ejim.2024.06.012_bib0002","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of lentiglobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.06.012_bib0003","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41578-019-0145-9","article-title":"Engineered materials for in vivo delivery of genome-editing machinery","volume":"4","author":"Tong","year":"2019","journal-title":"Nat Rev Mater"},{"issue":"7","key":"10.1016\/j.ejim.2024.06.012_bib0004","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ejim.2024.06.012_bib0005","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbad131","article-title":"Using traditional machine learning and deep learning methods for on- and off-target prediction in CRISPR\/Cas9: a review","volume":"24","author":"Sherkatghanad","year":"2023","journal-title":"Brief Bioinform"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524002528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524002528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T22:12:15Z","timestamp":1726351935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524002528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":5,"alternative-id":["S0953620524002528"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.06.012","relation":{},"ISSN":["0953-6205"],"issn-type":[{"type":"print","value":"0953-6205"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pioneering the future: CRISPR-Cas9 gene therapy for hereditary hemorrhagic telangiectasia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}